Oncothyreon, Inc. (ONTY) Starts Presentation at Rodman & Renshaw Global Investment Conference

Oncothyreon develops therapeutics products to treat various forms of cancer. The biopharmaceutical company’s lead candidate is a vaccine used in the treatment of non-small cell lung cancer, but it also has products designed to treat B-cell lymphoma and other diseases. Several of its therapies are in Phase I and Phase II trials. For more information, please visit the company’s website at www.oncothyreon.com.